The recent approval by the regulatory authorities in the United States of several HIV proteinase inhibitors as therapeutics for the treatment of AIDS confirms that virus proteinases are valid molecular targets in the search for new antiviral drugs. This review summarizes the available approaches that can be taken to discover virus proteinase inhibitors and reviews the current status of our knowledge with respect to virus proteinases in viruses of clinical significance other than HIV. The major focus is on proteinases identified in the viruses that cause the common cold, hepatitis C virus and the herpesviruses.
Introduction
Proteinases have long been recognized as valid targets for the development of inhibitors for. use as therapeutics in a number of serious human diseases. Renin, angiotensionconverting enzyme and endothelin are such targets in hypertension. In inflammatory disease, lnterleuktn-t-f-converting enzyme and tumour necrosis factor convertase are proteinase targets. Additional examples include the matrix metalloproteinases in the arthropathies and human metastases, and neutrophil elastase in emphysema and bronchitis. A major group of proteinases which has received much attention in recent years is that encoded by viruses and with respect to inhibitor studies, the focus has been very much on the proteinase of HIV. The recent approval by the US regulatory authorities of the HIV proteinase inhibitors Invirase (Hoffman La Roche), Crixivan (Merck and Co) and Norvir (Abbott) for the therapy of AIDS and the likelihood that other inhibitors will be considered for approval in the Received 22 May, 1996; revised 19 June, 1996; accepted 26 June, 1996. For correspondence: Tel. (0)1707 366532; Fax (0)1707 332053: E-mail jOhn.mills@roche.com © 1996 Blackwell Science Ltd future, confirms the validity of virus proteinases as tractable antiviral targets. This review focuses on other clinically significant viruses and considers the opportunities that are arising for developing proteinase inhibitors with therapeutic potential. For an extensive review of virus proteinases, the reader is referred to the reviews by Dougherty and Semler (1993) and Oprea et al. (1994) .
Virus proteinases as targets for drug discovery Virus proteinases are recognized as particularly good targets for drug discovery for several reasons.
'Achilles heel'
The virus-coded proteinases usually perform some essential function in virus replication and more often than not they are different from cellular proteinases, thus allowing them to avoid the host cells' proteinase inhibition control mechanisms. As such, the virus proteinase represents a vulnerability, an 'Achilles heel', that the drug hunters can use to their advantage in the drug design and development process.
Knowledge database
The 'classical' cellular proteinases have been classified into four groups (aspartic, metallo, serine and cysteine) based upon their catalytic mechanism and the geometry of their active site. There is an excellent database of information available with respect to each of these classes of proteinases which includes amino acid sequence, substrate specificity data, details of catalytic mechanism, inhibitor profiles and, in a steadily increasing number of cases, there is three-dimensional atomic X-ray crystallographic structural information. This reservoir of knowledge has come from many years of research on proteinases in academic and pharmaceutical research laboratories and is extremely useful in the early stages of research on recently identified virus proteinases. Analysis of the amino acid sequence, diagnostic inhibitor profile and biochemical properties of virus proteinases and comparison with the database of information on cellular enzymes facilitates classification of the virus enzyme into one of the four classes. This can be an important first step in the inhibitor design process. OJ I\)
S-
Cii"
"Number of independent X-ray structure co-ordinate datasets available in the Brookhaven Protein databank. Many structures are derived from enzyme-inhibitor co-crystals. A representative sample of the information available is summarized in Table I and includes examples of virus proteinases which now form part of the database, many of which will be discussed in this review.
Drug discovery strategy
A further advantage of virus proteinases as therapeutic targets relates to the drug discovery process itself. In most cases, a clear and well-defined drug discovery strategy can be planned which relies very much on synergy between scientists with expertise in molecular biology, biochemistry, enzymology, medicinal chemistry and biophysics.
A virus proteinase target is often tentatively identified by searching or 'mining' the predicted amino acid sequences of virus genes derived from virus genomic RNA or DNA sequences. Alternatively, the first hint of the presence of a virus proteinase may come from biological experiments that detect proteolytic activity in a virus-infected cell or a recombinant expression system. The readily-available techniques of molecular biology, particularly the polymerase chain reaction, facilitate the rapid cloning of the putative virus proteinase and substrates. These clones can be engineered into appropriate vectors for expression analysis in in-vitro transcription/translation assays, in host organisms such as E. coli or yeast or in cell lines using various promoters and vectors (e.g. baculovirus, vaccinia virus, Semliki Forest virus).
Virus-coded proteinase activity is usually confirmed by site-directed mutagenesis studies. Mutation of an active site residue, identified on the basis of amino acid sequence homology with other cellular and virus proteinases, enables the role of the proteinase in processing substrates to be characterized. The observation that a virus proteinase is responsible for the cleavage of one or more substrates is interpreted as evidence that the virus enzyme has an important and probably essential role in virus replication. The conclusive proof of this, however, requires the generation of a recombinant virus encoding an active site mutation in the proteinase or the identification and characterization of temperature-sensitive (ts) mutants. These experiments will often proceed in parallel with ensuing work to develop assays and identify inhibitors.
The next stage is to identify an expression and purification strategy that yields enzyme in sufficient quantity, purity and with the appropriate activity, to facilitate in-vitro assay development. Initiation of biochemical, enzymological and crystallographic studies can then follow. The best expression and purification strategy is often determined empirically and the approach that yields enzyme for inhibitor screening may not be the same as that which generates material for crystallography. The availability of purified, active enzyme facilitates in-vitro assay development. Peptide substrates based upon the predicted Viral proteinases review 283 cleavage sequences in the natural substrates are usually used in the first instance, with cleavage monitored by HPLC. Further developmental work usually generates an assay with a colorimetric, fluorometric or radioactive isotope detection methodology which may offer a number of advantages compared to HPLC measurements. An invitro assay allows more detailed biochemical and enzymological studies to be undertaken, generating important mechanistic data which can be used in the inhibitor design process.
Until an X-ray (or NMR) atomic structure of the proteinase is generated, molecular modelling, together with the information gathered with respect to the enzyme's substrate specificity and predicted catalytic mechanism, is used to initiate a rational design process to identify inhibitors. As the synthesis and evaluation of inhibitors proceeds, structure-activity relationships can be defined and lead compounds identified. The specificity of inhibitors may well be investigated at this stage to confirm that the compounds are selective inhibitors of the virus enzyme and not of related cellular enzymes. The design of potent selective inhibitors can be greatly enhanced when a three-dimensional (X-ray) structure of the enzyme at high resolution becomes available.
An alternative approach to inhibitor discovery will often proceed in parallel. The in-vitro assay first used to characterize the enzyme's activity is developed, optimized and adapted to a high throughput screening format. Robotics technology can then be used to screen libraries of proprietary compounds, combinatorial libraries and natural products. Natural products (e.g. bacterial and fungal broths) have, historically, been rich sources of proteinase inhibitors. Pepstatin, for example, the archetypal aspartic proteinase inhibitor, was originally isolated from an Actinomycetes broth (Aoyagi et al., 1971) . Broth screening may therefore generate one or more useful leads.
During the process of identifying lead compounds, efforts to generate cell-based (antiviral) assays and appropriate animal models, if not already available, will have been a further focus of research. The identification of compounds with potent antiviral activity in cell-based assays and animal models is followed by a pharmacodynamic and toxicological evaluation of the more promising compounds. An inhibitor with the desired properties for clinical evaluation will hopefully be identified at the end of this process.
HIV Paradigm
In the years following the publication of the HIV proviral genomic nucleotide sequence by Ratner et al. (1985) , the HIV-coded proteinase was subjected to the strategy summarized in the preceding section. The first HIV proteinase inhibitor to enter clinical trials was Ro 31-8959 (saquinavir) in 1991 and the details of how this compound was identified and developed at Hoffman La Roche have been described previously (Roberts et al., 1990; Mills, 1993 and Roberts and Redshaw, 1993) . Many HIV proteinase inhibitors have been, and continue to be, evaluated in clinical trials. The first proteinase inhibitor approved for AIDS therapy by the US regulatory authorities was saquinavir, in December 1995, followed by Crixivan (indinavir, Merck and Co) and Norvir (rltonavlr, Abbott) in March 1996. Although issues with respect to resistance and cross-resistance of HIV proteinase inhibitors (Roberts, 1996; Tisdale, 1996) and definition of the optimal combination therapy regime remain to be resolved, it is clear that the discovery and development of the HIV proteinase inhibitors serves as a paradigm. This paradigm confirms that virus proteinases are suitable molecular targets for the development of antiviral therapeutics and affirms the validity of investigating virus encoded proteinases in other viruses of clinical significance.
Given these observations with respect to HIV proteinase inhibitors, the current status of our knowledge with respect to other virus proteinases will be summarized and the potential for identifying antiviral drugs in the future will be addressed. The review focuses on proteinases in viruses where the associated disease causes a significant medical need and a low therapeutic or prophylactic success is evident. Consequently, some of the virus proteinases about which we know a great deal (e.g. poliovirus proteinase 3C), but where there is not a major therapeutic opportunity, will not be reviewed in detail.
The common cold syndrome
The common cold is usually a mild, self-limiting respiratory disease, but of very significant economic impact in terms of lost time at work. Serious consequences can also occur in patients with pre-existing respiratory and cardiovascular problems. The symptoms of the common cold, although caused by infection with a range of respiratory pathogens, are very similar. Fifty per cent of common colds are caused by rhinovirus infection, approximately 20% by coronavirus infection and the remainder are due to infection with either Coxsackie A or B virus, adenovirus, parainfluenza virus, reovirus or respiratory syncytial virus. Virus-coded proteinases have not been identified in parainfluenza virus or in respiratory syncytial virus; consequently, these viruses will not be discussed further in this review.
Rhinovirus
Rhinovirus is a member of the Picornaviridae which includes poliovirus, Coxsackie A and B virus, hepatitis A virus and foot and mouth disease virus. A common characteristic of the picornaviruses is their genomic organization and translational strategy. The genomic RNA acts as a monocistronic message and is initially translated as a precursor polyprotein which is subsequently processed to yield the mature virus products, both structural and nonstructural. The required proteolytic steps, which were first elucidated for poliovirus, can be separated into three categories based on the proteolytic entity required (reviewed in Lawson and Semler, 1990) . The capsid proteins precursor P1 is released cotranslationally by the virally encoded 2A proteinase (2A Pro ) . The final maturation cleavage that occurs in the VPO protein may be autocatalytic. All other cleavages within the virus polyprotein (most often at Gln-Gly junctions) are absolutely dependent on residues contained in the 3C Pro region. The 3C Pro polypeptide is itself the product of 3C Pro proteolytic activity, in that its amino and carboxyl termini are produced by cleavage at Gln-Gly junctions. During poliovirus replication however, a considerable fraction of the 3C Pro is found fused to the 3D polymerase. With respect to rhinovirus, biochemical experiments have clearly shown that the released form of 3C Pro is proteolytically active against a variety of protein and peptide substrates (Cordingley et al., 1989; Orr et al., 1989) .
Sequence alignments of picornavirus 3C proteinases show a small stretch of amino acids homologous to the Gly-X-Ser-Gly-Gly motif found at the active site of serine proteinases (Gorbalenya et al., 1986) , except that the nucleophilic serine is replaced with cysteine. The structure of human rhinovirus-14 3C proteinase has now been determined at 2.3 Aresolution (Matthews et al., 1994) and the data reveal that the enzyme is folded into two topologically equivalent six-stranded Bbarrels with a long shallow groove for substrate binding located between the two domains. Similar double B barrel polypeptide-folding motifs are found in trypsin-like pancreatic serine proteinases (Birktoft and Blow, 1972) and in Sindbis virus nucleocapsid core protein (Choi et al., 1991) . These proteins, however, have only very limited amino acid identity with rhinovirus 3C Pro • The catalytically important residues in rhinovirus 3C Pro , His-40, Glu-71 and Cys-146 form a linked cluster of three amino acids having an overall geometry similar to that of the Ser-His-Asp catalytic triad found in members of the trypsin-like family of serine proteinases (Birktoft and Blow, 1972) . These structural features clearly indicate that rhinovirus 3C Pro , notwithstanding the substitution of serine by cysteine as the active site nucleophile, is related to the classical trypsin-like serine proteinases rather than to the papain-like family of cysteine proteinases. Further studies on rhinovirus 14 3C Pro have been reported, including the generation of a fluorescence-based peptide substrate assay (Birch et al., 1995) and efforts to generate rhinovirus proteinase inhibitors have been described based upon chloromethyl ketone peptides (Korant, 1994) and more recently with glutaminederived aldehydes (Kaldor et al., 1995) . A high throughput screening strategy has also been employed to identify inhibitors of this virus proteinase (McCall et al., 1994) In addition to its role in polyprotein processing, rhinovirus 3C P ro has a second non-proteolytic function involving formation of the initiation complex needed for synthesis of positive-strand RNA. 3C P ro binds with a cloverleaf structure in the 5' non-coding region (Leong et sl., 1993; Walker et al., 1995) and the amino acid residues involved are located on the opposite side of the molecule from the active site (Matthews et al., 1994) .
The picornavirus 2A proteinase found in enteroviruses and rhinoviruses is a multifunctional virus gene product essential for efficient completion of the virus life cycle. Sequence alignments and structural modelling studies suggest that like 3C Pro , 2A Pro resembles the trypsin-like serine proteinases but utilizes an active-site cysteine residue as the nucleophile instead of serine . The substrate recognition properties of 2A Pro have been analysed in some detail (Hellen et al., 1992) and these studies indicate that the enzyme does not have strict requirementsfor specific amino acid residues near the scissile bond, although there are clearly preferred residues for efficient proteolytic cleavage. The 2A proteinase of human rhinovirus-2 has also been shown to combine 1 mole of zinc per mole of enzyme. Although the enzyme is not inhibited by metal chelating agents, zinc depletion does lead to a loss of proteolytic activity (Sommergruber et al., 1994a) and it has been suggested that the zinc ion may be required to maintain structural integrity.
As previously indicated, the 2A proteinase cleaves the nascent viral polyprotein resulting in liberation of the structural proteins' precursor from the rest of the non-structural polyprotein sequences. The enzyme is also involved in the process that ultimately results in the cleavage of p220, an integral component of eIF-4F, a eukaryotic initiation factor complex that normally interacts with capped cellular mRNAs as a prerequisite for ribosome binding. The complexities of the role of 2A in this process and its effect on viral and cellular protein translation are currently being dissected (Lu et al., 1995a; Ziegler et al., 1995) and may lead to the identification of new molecular targets or processes for inhibition which involve a virus proteinase.
Coxsackie viruses A and B
Coxsackieviruses A and B also belong to the Picornaviridae and, in addition to their involvement in respiratory disease, the Coxsackieviruses produce a remarkable variety of illnesses, the most serious of which is probably the involvement of Coxsackie B virus types 2-5 in infectious myocarditis. The proteinases of the
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Coxsackieviruses have not been as intensively studied as those of other members of the Picornaviridae but our knowledge with respect to the Coxsackievirus 2A (Sommergruber et al., 1994b; Lu et al., 1995a) and 3C proteinases (Miyashita et al., 1995) is steadily increasing and it is clear that the enzymes playa similar role in viral replication to their counterparts in rhinovirus.
Coronavirus
Human coronaviruses are important medical pathogens known to cause respiratory infections in children and adults and their involvement in human enteric disease seems likely. There are two major antigenic groups represented by the prototypes CV 229E and OC 43. The two groups are equally responsible for respiratory infections although CV 229E has been more extensively studied. The CV 229E genome is a positive-strand RNA of 27 277 nucleotides coding for at least eight functional open reading frames. In the infected cell, the viral gene products are expressed from genomic and subgenomic mRNAs. The subgenomic mRNAs form a 3' coterminal set and are synthesized via a process involving discontinuous transcription. The unique region of 229E genomic RNA (mRNA 1) encodes the viral polymerase (Herold et al., 1993) and its two open reading frames (ORF, 1a and 1b) are probably expressed via a frame shifting mechanism. Computerassisted analysis of the 1a ORF of murine coronavirus (mouse hepatitis virus), infectious bronchitis virus and the human coronavirus 229E (Gorbalenya et al., 1989) has identified motifs characteristic of both papain-like cysteine proteinases and proteinases with homology to the 3C Pro enzyme of picornavirus. Progress in cloning, expression and preliminary biochemical characterization of the murine (Lu etal., 1995b) and human (Ziebuhr etal., 1995) coronavirus 3C-like proteinase has recently been reported. This enzyme represents a potential antiviral target for the therapy of coronavirus disease.
The two papain-like proteinases encoded within the first open reading frame (ORF 1a) have been studied in the mouse coronavirus (murine hepatitis virus). The papainlike proteinase nearest the amino terminus of ORF 1a is responsible for the cleavage of the amino terminal protein, p28, and the specific cleavage site (Gly 247 and Val 248) has been mapped . The details with respect to the corresponding enzymes in the human coronavirus have yet to be reported.
Adenovirus
There are over 100 serotypes of adenovirus, 47 of which infect humans and are responsible for a range of conditions which include ocular and gastro-intestinal infections in addition to respiratory disease (Horwitz, 1990) . They are non-enveloped viruses with 34-36 kb double-strand DNA genomes with the potential to encode at least 50 proteins. The first suggestion that proteolytic processing was involved in adenovirus replication came from the characterization of the ts mutant H2ts1 (Hassel and Weber, 1978) . Subsequent genetic and biochemical studies identified a single amino acid change in the L3 open reading frame of the H2ts1 mutant that resulted in the production of non-infectious virions and the accumulation of precursor forms of a number of virus-coded proteins in the virion (Yeh-Kai et a/., 1983) . The endoproteinase encoded by the L3 open reading frame has a molecular weight of 23 kDa and has been produced from disrupted virions and recombinant expression systems. The use of synthetic peptides has enabled the substrate specificity to be investigated (Webster et a/., 1989a,b) . Early studies demonstrated that the endoproteinase had no recognizable amino acid motifs indicative of its role as a proteinase. Although initially classified as a serine proteinase , further sequence alignments of the endoproteinase from various adenovirus serotypes, mutagenesis and inhibitor studies (Grierson et a/., 1994; Rancourt et a/., 1994) confirmed that the adenovirus proteinase has a cysteine residue as the active site nucleophile and may represent a new sub-class of cysteine proteinases. The adenovirus proteinase is activated by a disulphide-Iinked peptide derived from the C terminus of the virus structural protein pV1 and a thiol-disulphide interchange mechanism of activation has been suggested (Webster et a/., 1993; Grierson et a/., 1994) . In an independent study, viral DNA, in addition to the pV1-derived peptide, has been identified as a cofactor (Mangel et a/., 1993) . The adenovirus proteinase has been shown to be involved in several processes during virus replication, including virus entry into cells (Cotten and Weber, 1995) and viral DNA replication by cleavage of both the genome-bound and the freely soluble preterminal protein . A role for proteinase in triggering the adenovirus maturation pathway has also been described (Matthews and Russell, 1995) . Given the essential nature of the adenovirus proteinase for virus replication and its multiple roles, it represents an attractive proteinase target for inhibition. Efforts to generate inhibitors have been reported (Cornish et a/., 1995) and progress towards generating an X-ray crystal structure (Keefe et a/., 1995) should assist in this process.
Reovirus
The Reoviridae (respiratory enteric orphan virus) comprises a family of RNA viruses that can infect the respiratory and intestinal tract. Reoviruses have a segmented double-strand RNA genome and the outer protein shell of the virion is composed principally of two structural proteins, J.tl and 0"3. The cleavage of ul, the capsid protein precursor, is complex and is probably mediated by two distinct proteolytic activities. The first J.tl cleavage event occurs between Asn-42 and Pro-43 generating J.tIC (Jayasuriyaet a/., 1988) . For this cleavage to proceed, J.tl must complex with 0"3. It had been suggested that 0"3 may possess a serine-like proteinase activity which was responsible for this cleavage. This hypothesis arose from the identification of amino acid sequences in the 0"3 protein that are also found in the picornavirus proteinases (Schiff et a/., 1988) . Mutagenesis studies, however, confirmed that the 0"3 domain which has homology to the picornavirus proteinases is not required for conversion of ul to J.tIC (Mabrouk and Lemay, 1994) . It has also been hypothesizedthat 0"3 may serve as a scaffold protein to facilitate J.tl cleavage by a ul self-cleavage reaction or by a cellular proteinase (Tillotson and Shatkin, 1992) . A further cleavage of J.tIC by a host proteinase which is essential for virion infection and pathogenesis has also been suggested (Nilbert and Field 1992) . Clearly, proteolytic processing has an important role in reovirus replication but the precise details have yet to be established.
It will be apparent from the foregoing discussion on the viruses that cause the common cold syndrome that proteinases coded for by rhinovirus, coronavirus, adenovirus and Coxsackieviruses A and B are, in principle, good antiviral targets. There are several issues, however, which have probably limited to some extent the investment into drug discovery for the viruses that cause the common cold. The major issue is that a specific virus proteinase inhibitor (or inhibitor for any other virus-specific target) is likely to be ineffective in many and possibly the majority of patients because the common cold syndrome has many aetiological agents. The development of effective therapeutics would require the concomitant development of rapid, inexpensive, home-based diagnostics to ensure the use of the appropriate virus specific drug. In addition, the generally mild, self-limiting nature of the disease and the observation that most symptoms probably result from an inflammatory response triggered by infection may limit the use of such antiviral agents to prophylactic use. Nevertheless, a 'cure for the common cold' is often cited as the 'Holy Grail' in viral disease therapy and as our understanding of the viruses that cause this disease continues to improve, we can remain optimistic about the prospect for effective antiviral drugs for prophylaxis and therapy.
Viral hepatitis
There is now a growing number of hepatotropic viruses that cause varying degrees of hepatitis. This review focuses on hepatitis viruses A, Band C which cause the majority of cases of acute and chronic virus hepatitis.
Hepatitis A virus
Hepatitis A virus (HAV), a member of the Picornaviridae, causes an acute, self-limiting disease, characterized by fever, nausea, abdominal pain and jaundice. Sequence alignments of the HAV genome with other picornaviruses (Cohen et a/., 1987) and preliminary analysis of the proteolytic activity of HAV polypeptides (Jia et a/., 1991; JOrgensen et a/., 1993) argued for a different regulation of proteolytic processing in HAV compared to poliovirus and rhinovirus. The 2A protein of HAV, for example, is devoid of proteolytic activity, whereas the autocatalytic activity of the HAV 3C Pro has been demonstrated in various recombinant systems (Gauss-MOiler et a/., 1991; Tesar et a/., 1994) . The substrate specificity of the HAV 3C proteinase has been investigated using natural substrates (Schultheiss et a/., 1994 (Schultheiss et a/., , 1995 . The atomic X-ray crystallographic structure of the HAV 3C proteinase has been determined to 2.3 A resolution (Allaire et a/., 1994) and this confirms the prediction that the enzyme is structurally related to the chymotrypsin-like serine proteinase family, but with a cysteine in place of a serine residue as the active site nucleophile. Allaire et at. (1994) conclude from their analysis of the data that HAV 3C proteinase has a catalytic mechanism involving only a cysteine-histidine dyad, which contrasts with the cysteine-histidine-glutamic acid triad observed in the rhinovirus 3C Pro (Matthews et a/., 1994) . The apparent similarities and differences between the picornavirus (cysteine) and cellular (serine) proteinases provided a fascinating glimpse at the evolutionary origins of the picornavirus 3C cysteine proteinases (Carrell and Lesk, 1994) . Potent peptide-based aldehyde inhibitors of HAV 3C Pro have recently been described (Malcolm et a/., 1995) and this represents a first step in the development of HAV proteinase inhibitors of potential therapeutic benefit. The current availability of effective prophylactic vaccines for HAV may, however, limit the future effort in identifying HAV antiviral therapeutics.
Hepatitis B virus
Hepatitis B virus causes polymorphic liver disease and is associated with the development of cirrhosis and hepatocellular carcinoma. The virus belongs to the Hepadnaviridae and replication of the DNA genome proceeds through a reverse transcription step. The involvement of reverse transcription in HBV replication and the homology at the nucleotide and predicted amino acid sequence level with retroviruses (Miller and Robinson, 1986) suggests that the hepadnaviruses and retroviruses may be genetically related. Hepadnaviruses were further shown to encode two proteinase-like sequences homologous to retroviral aspartic proteinase sequences (Miller, 1987) . One proteinase-like sequence was identified at the Viral proteinases review 287 amino terminus of the polymerase gene sequence, but this did not have the aspartic acid residue required for catalytic activity. A second domain found in the HBV core protein has 45% homology with an 85-amino acid region of HIV-1 proteinase, including the active site aspartic acid residue and flanking sequences. The observation that production of the secretory e antigen by proteolytic processing of the core antigen was inhibited by pepstatin, the specific inhibitor of aspartic proteinases (Jean-Jean et a/.,  1989) , supported the hypothesis that HBV may encode a proteinase. Mutagenesis studies directed at the conserved sequences in the HBV core gene, however, did not influence e antigen production and it was concluded that the HBV proteinase, if it exists, is functionally distinct from retroviral aspartic proteinases (Nassal et a/., 1989) . No further evidence indicating the role of a virus proteinase in HBV replication has emerged.
Hepatitis C virus
In contrast with hepatitis B virus, two virus encoded proteinase activities have been described for hepatitis C virus (HCV). HCV is the major aetiological agent of post transfusion and sporadic community-acquired non-A, non-B hepatitis. In the majority of cases HCV causes a persistent liver infection that eventually develops into cirrhosis or hepatocellular carcinoma. The molecular cloning and sequencing of the cDNA of HCV revealed that its genome is a positive-strand RNA (Choo et a/., 1989) which encodes a single open reading frame capable of expressing a polyprotein of about 3000 amino acids (reviewed by Matsuura and Miyamura, 1993) . In the absence of a satisfactory cell culture system for propagating the virus, studies of its mode of gene expression have depended upon the use of heterologous systems for protein expression. By these methods it has been established that the NS3 region of the polyprotein contains a serine proteinase domain which is responsible for cleavage of the downstream polyprotein in at least four places (Bartenschlager et a/., 1993 (Bartenschlager et a/., , 1994 Eckart et sl., 1993; Grakoui et a/., 1993a; Hijikata et a/., 1993a; Tomei et a/., 1993; Manabe et a/., 1994) . In these studies, processing between NS3 and NS4A was shown to be mediated by an intramolecular reaction, whereas cleavage at the other junctions (NS4A/NS4B, NS4B/NS5A, NS5A/NS5B) occurs in trans. In addition, the amino acid residues His-1083, Asp-1107 and Ser-1165 in the amino terminal domain of NS3 were shown to be essential for proteinase activity and have been predicted to form the catalytic triad of the enzyme's active site. By analogy with mutagenesis studies in yellow fever virus (Chambers et a/., 1990) this proteinase is probably essential for the production of infectious virus and hence represents a target for the development of inhibitors.
Comparison of the amino acid residues flanking each NS3 cleavage site for a number of HCV strains suggests a consensus that may contribute to the substrate specificity of the proteinase (Grakoui et a/., 1993b) . This sequence is defined as Asp/Glu-X-X-X-X-CysfThr J-Ser/Ala, where Asp/Glu is in the P6 position of the scissile bond, CysfThr is in the P1 position, Ser/Ala is in the P1' position and X is any amino acid. This unusual substrate specificity suggests that it should be possible to generate inhibitors which show a high degree of selectivity for the virus enzyme over cellular serine proteinases. Since the identification of the cleavage sites, the substrate requirements for the NS3 enzyme have been further probed and analysed by amino acid substitution (Kolykhalov et a/., 1994; Komuda et a/., 1994; Leinbach et a/., 1994 ) and a molecular model of the specificity pocket of the proteinase has been described (Pizzi et el., 1994) . Further biochemical characterization and inhibitor studies with known proteinase inhibitors have led to the classification of the NS3 proteinase as a member of the chymotrypsinlike serine proteinase family (Hahm et a/., 1995) .
The development of in-vitro assays for any virus proteinase is critical for inhibitor screening and such assays have been described for the NS3 enzyme. In-vitro NS3 proteinase activity has been observed with enzyme expressed and extracted from cells infected with recombinant vaccina virus vectors (Bouffard et a/., 1995) ; baculovirus vectors (Overton et a/., 1995) and in-vitro transcription/translation assays have also been used (D'Souza et et., 1994) . Recent progress in the purification of NS3 (SteinkOhler et a/., 1996) suggests that efforts to generate material for crystallographic studies are well in hand.
The availability of purified recombinant NS3 proteinase, in-vitro assays and our increasing knowledge with respect to the biochemistry and enzymology of the enzyme should enable rapid progress to be made in screening for and designing potent, selective inhibitors for use as therapeutic agents. In addition to generating inhibitors of the catalytic mechanism of the NS3 proteinase an additional approach is apparent with the observation that NS4A, a 54 amino acid hydrophobic peptide, is an essential proteinase cofactor (Bartenschlager et a/., 1994; Lin et a/., 1994) . Cleavage at the NS3A14A, NS4A14B and NS4B/5A junctions is absolutely dependent on NS4A, but processing between NS5A and NS5B can be mediated by NS3 alone. Several studies have demonstrated that NS3/4A can form a stable complex and deletion studies in combination with mutagenesis experiments have shown that the central NS4A domain is essential for proteinase activation (Lin et a/., 1995; Shimizu et el., 1996) . Sequences at the amino terminus of the NS3 proteinase have been shown to be involved in complex formation with NS4A (Bartenschlager et a/., 1994; Failla et a/., 1995; . Engineered NS4A peptides or synthetic compounds which act as dominant inhibitors of the activation function of authentic NS4A could, in principle, offer a novel approach to the abrogation of proteinase function. The availability of a cell-free trans-processing assay for NS3 with the NS4A cofactor should assist in evaluating this approach (Lin and Rice, 1995) .
Interestingly, a second HCV proteinase is encoded by the region of the HCV polyprotein which includes the Cterminal portion of the NS2 protein and the adjacent NS3 serine proteinase domain (Grakoui et a/., 1993c; Hijikata et el., 1993b) . This proteinase mediates cleavage at the NS2/NS3 junction and has been proposed to be a zincdependent metalloproteinase with His-952 and Cys-993 of the NS2 protein being required for activity.
Mutagenesis studies of the cleavage site and an investigation of the requirements for bimolecular cleavage (Reed et a/., 1995) have been undertaken. In addition, Santolini et at. (1995) observed that efficient cleavage at the NS2/3 junction is dependent on the synthesis of the protein precursor in the presence of functional microsomal membranes. Although our knowledge with respect to this enzyme is steadily increasing, the molecular mechanism of proteolytic processing at the NS2/3 site remains poorly understood. In principle, however, the NS2-3 proteinase with its role in intramolecular processing at the NS2/3 junction is an attractive proteinase target in HCV.
Herpesviruses
The Herpesviridae includes several human pathogenic viruses such as herpes simplex virus 1 and 2 (HSV-1 and HSV-2), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster virus (V2V) and human herpesvirus six (HHV-6). Herpesviruses have a doublestranded DNA genome of over 100 kilobases which replicates inside the nucleus of infected cells and is subsequently packaged into an intermediate capsid during virus maturation. A proteinase called 'assemblin' (reviewed by Gibson et et., 1994) , that functions during capsid assembly and virion maturation, is essential for the production of infectious virus (Preston et a/., 1983; Gao et a/., 1994) and represents a target for antiviral drugs. The proteinases and substrates of HSV-1 and CMV have been the focus of most attention, although the related proteinases of EBV (Donaghy and Jupp, 1995) and HHV-6 (Tigue et el., 1996) have been cloned, expressed, purified and characterized to a limited extent.
In HSV-1 the overlapping genes UL26 and UL26.5 were shown to encode the proteinase and its substrate (ICP35), respectively (Liu and Roizman, 1991a,b; Preston et a/., 1992) . The enzyme catalyzes the proteolytic maturation of the assembly protein (ICP35) generating VP22a, which is the most abundant protein in the intermediate B capsids. The catalytic domain of the proteinase is contained within the first 247 amino acids of the 635-amino acid protein (Weinheimer et a/., 1993) and is released from the precursor through cleavage by HSV proteinase itself (Deckman et et., 1992) . Amino acid sequence analysis of the autoproteolytic cleavage products of a modified UL26 gene expressed in E. coli revealed that the proteinase cleaves between alanine and serine residues at amino acids 247/248 and 610/611 (Dilanni et a/., 1993a) . On the basis of site specific mutagenesis experiments and analysis of the effect of various proteinase inhibitors, it has been proposed that the HSV-1 proteinase is a novel serine proteinase (Liu and Roizman, 1992; 1993) .
The human CMV UL80 open reading frame was reported to share homology with the UL26 open reading frame of HSV-1 (Chee et a/., 1990) and several studies have since confirmed that the CMV UL80 gene encodes a proteinase similar to that identified in HSV-1 (Welch et a/., 1991; Baum et el., 1993; Jones et a/., 1994) . Following the initial identification and preliminary characterization of the HSV and CMV enzymes, further progress has been made in understanding their enzymatic properties. Affinity labelling with diisopropylfluorophosphate indicates that Ser-132 in CMV (Stevens et el., 1994) and Ser-129 in HSV-1 is the catalytic nucleophile. Site-directed mutagenesis studies also indicate that one of only two histidine residues absolutely conserved in the proteinases of all members of the herpesvirus family is a strong candidate to be a second component of the active site (Welch et a/., 1993) . An aspartic acid, anticipated as the third component of a catalytic triad, has not been identified, although a glutamic acid which aligns within subgroups of the herpesvirus families has been proposed (Cox et a/., 1995) . The herpesvirus assemblin proteinase does not contain the characteristic sequence motifs found near the active-site serine residues of the chymotrypsin or subtilisin-like proteinases ( Table 1) . The herpes proteinases therefore appear to represent a new sub-class of the serine proteinase superfamily. This affords the prospect of designing highly selective virus specific inhibitors. In-vitro assays using peptide substrates have been described for HSV-1 proteinase (Dilanni et a/., 1993b) and for CMV proteinase and the kinetics of cleavage have been determined (reviewed in Gibson et a/., 1994) . It is clear that these enzymes cleave peptide substrates slowly and turnover rates are orders of magnitude lower than those observed with the viral proteinases of HIV-1 and rhinovirus.
An intriguing difference between the CMV and HSV-1 enzymes is the apparent cleavage site near the catalytic centre of the CMV proteinase (Baum et a/., 1993; Gibson et a/., 1993) . Cleavage at this internal site, however, has no apparent effect on the kinetic properties of the enzyme Viral proteinases review 289 (Holwerda et a/., 1994; O'Boyle et a/., 1995) and the function of this internal cleavage remains to be elucidated.
Progress in purification of the HSV-1 (Darke et a/., 1994) and CMV (Pinko eta/., 1995) proteinases has been reported and efforts to determine the X-ray structure are undoubtedly in progress. The availability of in-vitro assays using quenched fluorogenic peptide substrates (Handa et a/., 1995) will facilitate the generation of high throughput screening assays for identification of inhibitors.
These initial studies of the herpesvirus proteinases have shown them to be an intriguing and possibly unique enzyme family. As our knowledge improves we can expect significant progress to be made in identifying inhibitors of these essential enzymes which will hopefully be of clinical benefit in a number of diseases caused by members of the Herpesviridae.
Identification of proteinase inhibitors -future prospects
With the increasing amount of information becoming available with respect to many viral proteinases, what are the prospects of identifying potent proteinase inhibitors that will be the antiviral drugs of tomorrow? The availability of an in-vitro assay allows high volume 'random' screening of natural products, corporate databases of compounds, peptide, oligonucleotide and combinatorial chemical libraries, anyone of which may give rise to 'hit' compounds worthy of further evaluation as proteinase inhibitors. The availability of an X-ray crystallographic structure of the target enzyme at high resolution, ideally with a bound inhibitor, facilitates true rational design of more potent inhibitors. In the absence of a structure however, 'rational' design of inhibitors can still be performed by first characterizing the substrate specificity of the proteinase and then synthesizing peptides with similar features but with the hydrolyzable amide bond being replaced by a non-reactive 'isostere'. Further potency can be generated by adding specific moieties that are capable of forming transition-state analogue complexes with the enzyme. Optimization of the amino acid side chains and backbone can lead to further improvement in the activity of the inhibitors (reviewed by Kuntz, 1992) . We can expect to see the results of these approaches as applied to several of the viral proteinases described in this review in the not too distant future.
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